Aspen Pharmacare abandons lenacapavir license to focus on experimental alimatavir
Audio narration · Coming soon
Aspen Pharmacare has decided to drop its plans to produce a generic version of lenacapavir in South Africa. Instead, the company is concentrating its efforts on alimatavir, an experimental drug currently in phase III clinical trials.
Why this matters
PRISM scored this story 50/100 for interest.
Originally published by gnews